Argenx Se (ARGX) EBIT Margin (2016 - 2026)
Argenx Se (ARGX) posted quarterly EBIT Margin of 31.68% for Q2 2026, up 1049.0% year-on-year from 2.76% in Q2 2025, and up 4.38% on a QoQ basis from 30.35% in Q1 2026.
Argenx Se (ARGX) EBIT Margin (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported EBIT Margin for 11 consecutive years, with 31.68% the latest figure, recorded in Q2 2026.
- Quarterly EBIT Margin rose 1049.0% year-over-year to 31.68% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 30.4% (up 1539.0% YoY) and the FY2025 annual result came in at 24.81%, up 2577.0% from the prior year.
- EBIT Margin advanced to 31.68% in Q2 2026 per ARGX's latest filing, from 30.35% in the prior quarter.
- Over the last five years, EBIT Margin for ARGX reached as high as 1052.43% in Q1 2022 and fell as low as 828.51% in Q2 2022.
- A 5-year average of 33.3% and a median of 23.97% in 2023 frame the typical range for EBIT Margin.
- The largest YoY upside for EBIT Margin was 2000000000 bps in 2022 against a maximum downside of 2000000000 bps in 2022.
- Year by year, EBIT Margin stood at 65.99% in 2022, then surged by 44 bps to 37.03% in 2023, then surged by 138 bps to 13.98% in 2024, then surged by 104 bps to 28.59% in 2025, then grew by 11 bps to 31.68% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 31.68%, 30.35%, and 28.59% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 23.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.68% |
| Mar 31, 2026 | 30.35% |
| Dec 31, 2025 | 28.59% |
| Sep 30, 2025 | 30.72% |
| Jun 30, 2025 | 21.20% |
| Mar 31, 2025 | 17.59% |
| Dec 31, 2024 | 13.98% |
| Sep 30, 2024 | 2.48% |
| Jun 30, 2024 | 9.52% |
| Mar 31, 2024 | 23.46% |
| Dec 31, 2023 | -37.03% |
| Sep 30, 2023 | 24.49% |
| Jun 30, 2023 | 37.91% |
| Mar 31, 2023 | 47.58% |
| Dec 31, 2022 | -65.99% |
| Sep 30, 2022 | 158.87% |
| Jun 30, 2022 | -828.51% |
| Mar 31, 2022 | 1,052.43% |
| Dec 31, 2021 | -887.37% |
| Sep 30, 2021 | 0.00% |